Roivant Sciences Ltd. (NASDAQ:ROIV – Get Rating) Director Financial Lp Qvt sold 5,656,081 shares of the company’s stock in a transaction on Thursday, November 10th. The stock was sold at an average price of $4.75, for a total transaction of $26,866,384.75. Following the completion of the transaction, the director now directly owns 5,470,181 shares of the company’s stock, valued at approximately $25,983,359.75. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.
Roivant Sciences Stock Up 2.5 %
ROIV opened at $5.29 on Tuesday. The firm has a 50-day simple moving average of $4.20 and a two-hundred day simple moving average of $4.08. Roivant Sciences Ltd. has a 52 week low of $2.52 and a 52 week high of $16.76. The company has a market capitalization of $3.72 billion, a PE ratio of -3.31 and a beta of 1.89. The company has a quick ratio of 6.20, a current ratio of 6.20 and a debt-to-equity ratio of 0.22.
Roivant Sciences (NASDAQ:ROIV – Get Rating) last released its quarterly earnings data on Monday, August 15th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.18). Roivant Sciences had a negative net margin of 2,110.83% and a negative return on equity of 68.61%. The company had revenue of $4.32 million for the quarter, compared to the consensus estimate of $6.45 million. Analysts forecast that Roivant Sciences Ltd. will post -1.72 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
Several brokerages recently weighed in on ROIV. Citigroup upped their target price on shares of Roivant Sciences from $9.00 to $10.00 and gave the stock a “buy” rating in a report on Tuesday, August 16th. JPMorgan Chase & Co. began coverage on shares of Roivant Sciences in a report on Thursday, October 27th. They issued an “overweight” rating and a $7.00 target price for the company. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, Roivant Sciences currently has a consensus rating of “Buy” and an average price target of $10.83.
Roivant Sciences Company Profile
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia.
- Get a free copy of the StockNews.com research report on Roivant Sciences (ROIV)
- Wayfair Still Has Its Fair Share of Issues
- Take Two Interactive Software Stock is Taking One Step Back
- Why did NIO take a $581.11 million loss last quarter?
- This Mid-Cap Tech Stock Embodies Diversified Growth
- Is It Time To Take A Ride With Joby Aviation’s EV Innovations?
Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.